LS Investment Advisors LLC decreased its stake in Humana Inc. (NYSE:HUM) by 2.3% during the second quarter, Holdings Channel reports. The firm owned 4,364 shares of the insurance provider’s stock after selling 101 shares during the period. LS Investment Advisors LLC’s holdings in Humana were worth $1,050,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Humana by 2,281.7% in the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock valued at $2,553,487,000 after buying an additional 11,867,056 shares during the period. FMR LLC increased its position in Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock valued at $1,041,184,000 after buying an additional 1,851,197 shares during the period. Renaissance Technologies LLC increased its position in Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock valued at $554,867,000 after buying an additional 1,231,400 shares during the period. Wellington Management Group LLP increased its position in Humana by 2,651.1% in the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock valued at $159,915,000 after buying an additional 747,557 shares during the period. Finally, AQR Capital Management LLC increased its position in Humana by 413.8% in the first quarter. AQR Capital Management LLC now owns 736,019 shares of the insurance provider’s stock valued at $151,723,000 after buying an additional 592,772 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Shares of Humana Inc. (NYSE:HUM) opened at 235.01 on Friday. The stock has a market cap of $33.92 billion, a PE ratio of 23.95 and a beta of 0.91. The stock’s 50 day moving average price is $235.90 and its 200-day moving average price is $218.69. Humana Inc. has a one year low of $163.50 and a one year high of $243.74.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, May 3rd. The insurance provider reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.55 by $0.20. The firm had revenue of $13.76 billion during the quarter, compared to the consensus estimate of $13.61 billion. Humana had a return on equity of 14.38% and a net margin of 2.71%. During the same period in the prior year, the business earned $1.86 EPS. On average, equities analysts predict that Humana Inc. will post $11.15 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/07/21/ls-investment-advisors-llc-decreases-stake-in-humana-inc-hum.html.

HUM has been the subject of several research reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $237.00 price target on shares of Humana in a research note on Friday, March 24th. Deutsche Bank AG initiated coverage on Humana in a research note on Wednesday, April 5th. They set a “hold” rating and a $216.00 price target for the company. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $237.00 price target for the company in a research note on Tuesday, April 18th. Evercore ISI reaffirmed an “outperform” rating and set a $240.00 price target on shares of Humana in a research note on Tuesday, April 25th. Finally, Citigroup Inc. initiated coverage on Humana in a research note on Wednesday, June 28th. They set a “buy” rating and a $275.00 price target for the company. Ten investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $231.00.

In related news, VP Timothy S. Huval sold 13,939 shares of the stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $225.86, for a total value of $3,148,262.54. Following the completion of the sale, the vice president now directly owns 23,639 shares of the company’s stock, valued at approximately $5,339,104.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Heidi S. Margulis sold 1,500 shares of the stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the completion of the sale, the vice president now directly owns 8,150 shares of the company’s stock, valued at $1,890,474. The disclosure for this sale can be found here. Over the last three months, insiders sold 143,241 shares of company stock valued at $32,446,903. Company insiders own 0.80% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.